Research programme: small molecule therapeutics - Aqilion
Alternative Names: PolarisLatest Information Update: 13 Oct 2020
At a glance
- Originator Aqilion
- Class Anti-inflammatories; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation